Abstract:Brain perineuronal nets (PNNs) are vital for neurocircuit stability and changes in their abundance and composition have been linked to Alzheimer's disease (AD) progression. In this work, we investigated age‐associated PNN changes in transgenic mice with tauopathy‐related AD neuropathology. 9‐month‐old PS19 (P301S) mice exhibited changes in PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) composition and abundance, but not the underlying CS proteoglycan (CSPG) core proteins, in association with pTau, gliosis, and neurodegeneration. In contrast, Tau4RTg2652 mice showed stable PNNs despite pTau accumulation, emphasizing the importance of neuroinflammation on PNN glycan integrity in AD. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by clinical symptoms of memory and cognitive deficiencies. Postmortem evaluation of AD brain tissue shows proteinopathy that closely associate with the progression of this dementing disorder, including the accumulation of extracellular beta amyloid (Aβ) and intracellular hyperphosphorylated tau (pTau) with neurofibrillary tangles (NFTs). Current therapies targeting Aβ have limited clinical efficacy and life‐threatening side effects and highlight the need for alternative treatments targeting pTau and other pathophysiologic mechanisms driving AD pathogenesis. The brain's extracellular matrices (ECM), particularly perineuronal nets (PNNs), play a crucial role in brain functioning and neurocircuit stability, and reorganization of these unique PNN matrices has been associated with the progression of AD and accumulation of pTau in humans. We hypothesize that AD‐associated changes in PNNs may in part be driven by the accumulation of pTau within the brain. In this work, we investigated whether the presence of pTau influenced PNN structural integrity and PNN chondroitin sulfate‐glycosaminoglycan (CS‐GAG) compositional changes in two transgenic mouse models expressing tauopathy‐related AD pathology, PS19 (P301S) and Tau4RTg2652 mice. We show that PS19 mice exhibit an age‐dependent loss of hippocampal PNN CS‐GAGs, but not the underlying aggrecan core protein structures, in association with pTau accumulation, gliosis, and neurodegeneration. The loss of PNN CS‐GAGs were linked to shifts in CS‐GAG sulfation patterns to favor the neuroregenerative isomer, 2S6S‐CS. Conversely, Tau4RTg2652 mice exhibit stable PNN structures and normal CS‐GAG isomer composition despite robust pTau accumulation, suggesting a critical interaction between neuronal PNN glycan integrity and neighboring glial cell activation. Overall, our findings provide insights into the complex relationship between PNN CS‐GAGs, pTau pathology, gliosis, and neurodegeneration in mouse models of tauopathy, and offer new therapeutic insights and targets for AD treatment.

Tau‐mediated synaptic dysfunction is coupled with HCN channelopathy

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Locus coeruleus vulnerability to tau hyperphosphorylation in a rat model

Hyperphosphorylated Human Tau Accumulates at the Synapse, Localizing on Synaptic Mitochondrial Outer Membranes and Disrupting Respiration in a Mouse Model of Tauopathy

Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology

Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss

The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways

Tau Accumulation Induces Synaptic Impairment and Memory Deficit by Calcineurin-Mediated Inactivation of Nuclear CaMKIV/CREB Signaling

P301S‐hTau Acetylates KEAP1 to Trigger Synaptic Toxicity Via Inhibiting NRF2/ARE Pathway: A Novel Mechanism Underlying Htau‐induced Synaptic Toxicities

Tau Pathology Promotes the Reorganization of the Extracellular Matrix and Inhibits the Formation of Perineuronal Nets by Regulating the Expression and the Distribution of Hyaluronic Acid Synthases

Chronic Neuronal Hyperexcitation Exacerbates Tau Propagation in a Mouse Model of Tauopathy

Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer’s disease and other tauopathies

Tau P301L disengages from the proteosome core complex and neurogranin coincident with enhanced neuronal network excitability

Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration

Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration

Convergence of presenilin- and tau-mediated pathways on axonal trafficking and neuronal function.

Oligomeric, phosphorylated, and truncated tau and spliceosome pathology within the entorhinal-hippocampal connectome across stages of Alzheimer's disease

Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss

Pro-aggregant Tau impairs mossy fiber plasticity due to structural changes and Ca++ dysregulation

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia

Behavioral and Neurophysiological Implications of Pathological Human Tau Expression in Serotonin Neurons